• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Delcath Systems Inc.

    8/15/25 4:46:24 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    S-8 1 d446811ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 15, 2025

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    DELCATH SYSTEMS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   06-1245881

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    566 Queensbury Avenue

    Queensbury, NY 12804

    (Address of Principal Executive Offices) (Zip Code)

    Delcath Systems, Inc. Omnibus 2020 Equity Incentive Plan

    Delcath Systems, Inc. 2021 Employee Stock Purchase Plan

    Delcath Systems, Inc. 2023 Inducement Plan

    (Full title of the plan)

    Gerard Michel

    Chief Executive Officer

    Delcath Systems, Inc.

    566 Queensbury Avenue

    Queensbury, NY 12804

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    (212) 489-2100

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    David Hoffman

    General Counsel

    Delcath Systems, Inc.

    566 Queensbury Avenue

    Queensbury, NY 12804

     

    Ryan Sansom

    Christina Roupas

    Cooley LLP

    500 Boylston Street

    Boston, MA 02116-3736

    (617) 937 2335

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    INTRODUCTION

    This Registration Statement on Form S-8 is being filed by Delcath Systems, Inc. (the “Registrant” or the “Company”) for the purposes of registering an additional 2,950,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) consisting of:

     

      •  

    2,200,000 shares of Common Stock issuable under the Company’s Omnibus 2020 Equity Incentive Plan, as amended (the “2020 EIP” and such amendment, the “2020 EIP Amendment”);

     

      •  

    300,000 shares of Common Stock issuable under the Company’s 2021 Employee Stock Purchase Plan, as amended (the “2021 ESPP” and such amendment, the “2021 ESPP Amendment”); and

     

      •  

    450,000 shares of Common Stock issuable under the Company’s 2023 Inducement Awards Plan (the “Inducement Plan” and such amendment, the “Inducement Plan Amendment”).

    The 2020 EIP Amendment and 2021 ESPP Amendment were adopted by the Company’s Board of Directors on February 7, 2025, subject to stockholder approval, which was obtained at the Annual Meeting of Stockholders held on May 15, 2025. The Inducement Plan Amendment was adopted by the Company’s Board of Directors on February 5, 2025 and May 14, 2025.

    The Shares being registered are in addition to the shares of Common Stock registered on (i) the Registrant’s Form S-8 filed with the Commission on December 16, 2020 (File No. 333-251385), (ii) the Registrant’s  Form S-8 filed with the Commission on January 5, 2022 (File No. 333-262022), (iii) the Registrant’s Form S-8 filed with the Commission on May 25, 2022 (File No. 333-265202) and (iv) the Registrant’s Form S-8 filed with the Commission on December 15, 2023 (File No. 333- 276090) and (v) the Registrant’s  Form S-8 filed with the Commission on June 28, 2024 (File No. 333- 280550) (collectively, the “Prior Registration Statements”).

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2020 EIP, the 2021 ESPP and the Inducement Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3 Incorporation of Documents by Reference.

    The following documents filed with the Commission by the Registrant, pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (1)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on March 6, 2025;

     

    (2)

    the Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March  31, 2025 and June 30, 2025, filed with the Commission on May 8, 2025 and August 6, 2025, respectively;


    (3)

    the Registrant’s Current Reports on Form 8-K filed with the Commission on January  13, 2025, March  6, 2025, March  21, 2025, May  8, 2025, May  16, 2025, May  22, 2025, and August 15, 2025;

     

    (4)

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2024, from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 1, 2025; and

     

    (5)

    the description of the Common Stock of the Registrant set forth in the Registrant’s registration statements pursuant to Section  12 of the Exchange Act, and any amendment or report filed for the purpose of updating such description, including Exhibit 4.9 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8 Exhibits.

    The following exhibits are furnished with this Registration Statement:

     

    Exhibit
    No.
       Description of Exhibits
      4.1    Amended and Restated Certificate of Incorporation of Delcath Systems, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1/A filed with the Commission on September 25, 2019)
      4.2    Amendment to the Amended and Restated Certificate of Incorporation of Delcath Systems, Inc. dated October  17, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 23, 2019)
      4.3    Certificate of Correction to Amendment to the Amended and Restated Certificate of Incorporation of Delcath Systems, Inc. dated October  22, 2019 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on October 23, 2019)
      4.4    Amendment to the Amended and Restated Certificate of Incorporation of Delcath Systems, Inc., effective December  24, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 30, 2019)
      4.5    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Delcath Systems, Inc. dated November  23, 2020 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 24, 2020)
      4.8    Amended and Restated Bylaws, dated August  12, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on August 15, 2025)
      4.9    Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 6, 2025)
      4.10    Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 6, 2025)
      4.11    Delcath Systems, Inc. 2023 Inducement Awards Plan, as amended (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 6, 2025)
      5.1*    Opinion of Cooley, LLP
     23.1*    Consent of Cooley, LLP (included in Exhibit 5.1)
     23.2*    Consent of Marcum LLP
     24.1*    Power of Attorney (included on signature page of this Registration Statement)
    107*    Calculation of Filing Fee Table
     
    *

    Filed Herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Queensbury, State of New York on the 15th day of August, 2025.

     

    DELCATH SYSTEMS, INC.
    By:   /s/ Gerard Michel
      Gerard Michel
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Gerard Michel, Sandra Pennell and David Hoffman as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.


    SIGNATURE

      

    TITLE

     

    DATE

    /s/ Gerard Michel

    Gerard Michel

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

      August 15, 2025

    /s/ Sandra Pennell

    Sandra Pennell

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      August 15, 2025

    /s/ John R. Sylvester

    John R. Sylvester

       Chairman of the Board   August 15, 2025

    /s/ Gilad Aharon

    Gilad Aharon

       Director   August 15, 2025

    /s/ Elizabeth Czerepak

    Elizabeth Czerepak

       Director   August 15, 2025

    /s/ Steven Salamon

    Steven Salamon

       Director   August 15, 2025

    /s/ Bridget Martell

    Bridget Martell

       Director   August 15, 2025
    Get the next $DCTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. Approximately 90 patients will be enrolled

    8/19/25 8:30:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in the second quarter of 2024 CHEMOSAT® revenue of $1.7 million, compared to $1.2 million in the second quarter of 2024 Gross margins of 86%, compared to 80% in the second q

    8/6/25 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (P

    7/29/25 4:01:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    SEC Filings

    View All

    SEC Form S-8 filed by Delcath Systems Inc.

    S-8 - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    8/15/25 4:46:24 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Delcath Systems Inc.

    8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    8/15/25 4:15:25 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Delcath Systems Inc.

    10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    8/6/25 9:14:02 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Delcath with a new price target

    Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

    6/28/24 8:18:39 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on Delcath with a new price target

    Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

    5/14/24 7:58:22 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity resumed coverage on Delcath with a new price target

    Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

    7/26/22 9:10:21 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/20/24 8:00:14 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/20/24 7:44:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    12/14/23 4:20:16 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Vukovic Vojo exercised 42,000 shares at a strike of $4.78, increasing direct ownership by 33% to 168,882 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    6/13/25 5:22:47 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Czerepak Elizabeth

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    5/19/25 4:10:12 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Sylvester John Richard

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    5/19/25 4:10:16 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Financials

    Live finance-specific insights

    View All

    Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in the second quarter of 2024 CHEMOSAT® revenue of $1.7 million, compared to $1.2 million in the second quarter of 2024 Gross margins of 86%, compared to 80% in the second q

    8/6/25 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Host Second Quarter 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1723203&tp_key=fbe0333159 A replay of the webinar will be availab

    7/23/25 4:01:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Reports First Quarter 2025 Results and Business Highlights

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

    5/8/25 7:30:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

    SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 7:02:01 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Leadership Updates

    Live Leadership Updates

    View All

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

    Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

    5/28/24 9:30:00 AM ET
    $ACHV
    $ALGS
    $DCTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medical/Dental Instruments

    Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

    NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

    3/18/24 5:20:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care